Saturday, July 11, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 3 of 25
  1. Lutikizumab, Placebo of Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial
  2. MEDI4736 Placebo, DURVALUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients

    phase 3 small molecule active

    1 trial
  3. MITAPIVAT, Placebo for Mitapivat

    Lacuna Pharma Pty Ltd

    Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial
  4. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial
  5. MK-0616, Placebo to MK-0616 - Tablet

    Merck Sharp and Dohme

    ASCVD - Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial
  6. MK-6194, Placebo for MK-6194

    Merck Sharp and Dohme

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial
  7. MT-7117 Formulation Code C, MT-7117 Placebo

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria or X-Linked Protoporphyria

    phase 3 small molecule active

    1 trial
  8. Matched placebo for product, Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 3 small molecule active

    1 trial
  9. Matched placebo for test product, Duvakitug

    Sanofi-aventis Healthcare Pty Ltd

    Immune system disseases

    phase 3 small molecule active

    1 trial
  10. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial
  11. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial
  12. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial
  13. Matching Placebo

    IRONWOOD PHARMACEUTICALS INC

    Chronic Constipation

    phase 3 small molecule completed

    1 trial
  14. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial
  15. Matching Placebo for TAK-279, ZASOCITINIB

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial
  16. Matching Placebo for Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial
  17. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial
  18. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial
  19. Mavorixafor, Mavorixafor Placebo Capsules

    X4 Pharmaceuticals, Inc

    Neutropenias

    phase 3 small molecule active

    1 trial
  20. Mavorixafor, Placebo to Test IMP

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial
  21. Mezagitamab, Placebo matching for Mezagitamab

    Takeda

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial
  22. Mitapivat Matched Placebo

    Agios Netherlands B.V.

    Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial
  23. Modiodal 100 mg tabletten, PLACEBO

    Disc Medicine

    Inflammatory bowel disease, Fatigue

    phase 3 small molecule active

    1 trial
  24. NIFEDIPINE, Placebo of Nifedipine

    Pari Pharma GmbH

    obstetric_pathological delivery

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.